ClinicalTrials.gg
Not yet recruitingNCT07949370PRIMEUpdated Nov 19, 2026

A Phase 2 Study of Dynamic BH3 Profiling (DBP) Guided Combination Therapy in Subjects With R/R AML

A Phase 2 interventional study of Dynamic BH3 Profiling and Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia (AML), sponsored by Dana-Farber Cancer Institute. Not yet recruiting at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-19.

Primary conditionLeukemia, Myeloid, AcuteRegistry: RecurrenceReclassifiedWhy we changed it
Registry
Recurrence — the first condition term the registry derived for this study.
ClinicalTrials.gg
Leukemia, Myeloid, Acute
Why
  1. Recurrence describes something many studies share rather than a condition a study is about.
  2. The study's listed conditions name Leukemia, Myeloid, Acute.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Dana-Farber Cancer Institute · Phase 2, Interventional, and Treatment

How we know

Updated Nov 19, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
40
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 27 studies in Leukemia, Myeloid, Acute by Dana-Farber Cancer Institute — 7 open to participants now, 11 under way, none of them phase 3. Leukemia, Myeloid, Acute · Dana-Farber Cancer Institute.

Planned enrollment
8th of 24
40 · median 30
Started
2027
the only one that year
Phase 2
6 of 27
1 open now
Primary completion
2029-12
later than 10 of 10 live
Registered
27th of 27
by date

Among the 27 studies in Leukemia, Myeloid, Acute by Dana-Farber Cancer Institute, this one is the 8th largest by planned enrollment of the 24 interventional ones that give a count, is the only one that started in 2027, is one of 6 in phase 2, reaches primary completion later than 10 of the 10 other live ones, and was the 27th registered.

Leukemia, Myeloid, Acute

3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 813 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

7 of the 27 studies in Leukemia, Myeloid, Acute by Dana-Farber Cancer Institute are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 621 Leukemia, Myeloid, Acute studies recruiting now, 361 (58%) set no upper age limit and 220 (35%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies in Leukemia, Myeloid, Acute by Dana-Farber Cancer Institute, or all of them as a file.
02

Study summary

This study aims to evaluate the feasibility and efficacy of using the dynamic BH3 profiling (DBP) assay as a biomarker to guide venetoclax-based combination therapy for participants with relapsed or refractory acute myeloid leukemia (AML).

Read the detailed description

This is a phase 2, single-center, interventional study evaluating the feasibility and efficacy of using the dynamic BH3 profiling (DBP) assay as a biomarker to guide venetoclax-based combination therapy for participants with relapsed or refractory acute myeloid leukemia (AML). The DBP assay is a flow cytometry-based test (functional biomarker) performed on subject biospecimen (bone marrow aspirate) to measure drug-induced apoptotic priming against a pre-set panel of drugs, which can help to identify potentially effective drug combinations. Eligible participants will undergo biomarker screening, and the Protocol Tumor Board will review DBP results and clinical data to assign treatment. Following subjects on assigned treatment for safety and efficacy is part of the trial. Up to six venetoclax-based combination regimens are available. Participants will continue to receive assigned therapy as long as they are benefiting and tolerating treatment. The study will enroll up to 40 participants for treatment assignments, with up to 75 screened. Study procedures include screening, biomarker testing, treatment, disease response assessments, and follow-up for up to one year after last treatment.

03

Conditions studied

  • Relapsed or Refractory Acute Myeloid Leukemia (AML)

Browse trials for

Keywords

  • Refractory Acute Myeloid Leukemia
  • Relapsed Acute Myeloid Leukemia
  • Functional biomarker
  • Dynamic BH3 profiling
04

In context

Leukemia, Myeloid, Acute Reclassified

3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 813 are open to participants now.

This study's planned enrollment of 40 is close to the median of 40 across 3,007 interventional studies indexed under Leukemia, Myeloid, Acute.

Browse Leukemia, Myeloid, Acute studies →

Lead sponsor

Dana-Farber Cancer Institute is the lead sponsor of 836 studies on the registry; 121 are open to participants now.

Of its 114 completed or terminated interventional studies of FDA-regulated products, 78 (68%) have results posted.

Compared within Leukemia, Myeloid, Acute, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Recurrence. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Willing to undergo a bone marrow aspirate for biomarker testing.
  • Participants must have a diagnosis by WHO 2006 of one of the following:

    • Participants with AML must have at least 5% morphologic marrow blasts to be eligible. Extramedullary disease allowed but marrow involvement required.
    • Participants with Refractory AML are defined as those without a complete remission after two courses (or cycles) of any remission-induction regimen (intensive chemotherapy or less intensive regimen such as hypomethylating agent-venetoclax based treatment or low-dose cytarabine agent-venetoclax based treatment).
    • Participants with Secondary AML arising out of a previously treated prior myeloid neoplasm treated with intensive chemotherapy or at least two cycles of HMA/venetoclax-based treatment.
    • Participants may also be Relapsed/Refractory.
  • performance status ≤ 2 (see Appendix A)
  • Participants decline, must not be eligible or are not recommended by treating provider to receive immediate transplantation or available FDA-approved AML regimens.
  • Participants must meet the following organ function as defined below:

    • total ≤ 3 x institutional (ULN) unless considered to be due to leukemic organ involvement or Gilbert's disease. For participants with Gilbert's syndrome, participants may enroll if direct bilirubin ≤ 3xULN
    • (SGOT) and ALT(SGPT) ≤ 3 × institutional ULN
    • ≥ 30mL/min using Cockroft Gault formula
  • If male, even if surgically sterilized (i.e., status post-vasectomy), participant must agree to use adequate barrier prior to the study, for the duration of study participation, and 6 months after completion of study drug administration, or agree to practice true abstinence, when this is in line with the preferred and usual lifestyle of the participant. (Periodic abstinence [e.g., calendar, ovulation, symptothermal, postovulation methods for the female partner] withdrawal, spermicides only, and lactational amenorrhea are not acceptable methods of contraception.)
  • If female, participant must be either:

    • (surgically sterile or age > 55 years with no menses for 12 or more months without an alternative medical cause or age 55 or less with no menses for 12 or more months without an alternative medical cause AND an FSH level >40 IU/L) or
    • Women of must agree to use adequate contraception (defined as 1 highly effective method [hormonal] and 1 additional effective [barrier] method of birth control at the same time) 30 days prior to study entry, for the duration of study participation, and through 6 months after the last dose of study drug or agree to practice true abstinence when this is in line with the preferred and usual lifestyle of the participant. Female and male condoms should not be used together. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post ovulation methods), withdrawal, spermicides only, and lactational amenorrhea are not acceptable methods of contraception.
    • Women of childbearing potential: Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately.
    • Women of childbearing potential: Participant must have a negative serum beta-HCG test result (local labs are allowed) at screening. Repeat testing is required within 72 hours prior to first study dose (local labs are allowed).
  • White blood cell count \< 25,000/L prior to first dose on study protocol treatment. Hydroxyurea or leukapheresis are permitted to meet this criterion (hydroxyurea may be resumed after biomarker collection takes place).
  • Ability to understand and the willingness to sign a written document.
  • For combination venetoclax, azacitidine, and tagraxofusp assignment, must also meet the following organ function criteria:

    • Creatinine clearance (measured by Cockcroft-Gault formula or measured by 24-hour urine collection) ≥ 45 mL/minute; participants between 18 and 74 years of age may have creatinine clearance ≥ 30 mL/minute
    • Albumin > 3.2 g/dL (administration of albumin is permitted to achieve albumin eligibility if the baseline serum albumin is ≥ 3.0g/dL)
    • Total bilirubin ≤ 1.5 x upper limit of normal (ULN) except in participants with Gilbert's syndrome. Participants with Gilbert's syndrome may enroll if direct bilirubin ≤ 3 x ULN of the direct bilirubin.
  • For combination venetoclax, azacitidine, and revumenib assignment, must also meet the following organ function criteria:
  • Total bilirubin ≤ 2.0 x upper limit of normal (ULN) except in participants with Gilbert's syndrome. Participants with Gilbert's syndrome may enroll if direct bilirubin ≤ 3.0 x ULN of the direct bilirubin.

Exclusion criteria

Exclusion Criteria:

  • During biomarker collection: For purpose of dynamic BH3 profiling assay (biomarker) to optimize cell viability, participants must not be on any anti-leukemic therapy for at least 5 days prior to bone marrow aspirate collection with the exception of hydroxyurea which must be held at least 48 hours prior to aspirate collection. Note: hydroxyurea use is allowed immediately after bone marrow aspirate collection if clinically indicated.
  • Participants who have had chemotherapy (with exception of hydroxyurea and/or dexamethasone which are allowed) or radiotherapy or therapy within 5 half-lives or 14 days (whichever is shorter) prior to starting treatment on study.
  • More than two prior AML-directed salvage regimens defined as any given for a indication (excluding initial induction regimen, transplant, donor lymphocyte infusion, hydroxyurea, cytarabine for cytoreduction purposes).
  • Venetoclax within 14 days prior to starting treatment on study.
  • Any prior investigational therapy-related AEs must be grade 1 or at baseline prior to first dose on study (except for alopecia).
  • Has known acute promyelocytic leukemia.
  • Concurrent use of medications that are moderate or strong CYP450 inducers within 7 days of first dose on study. Because the lists of these agents are constantly changing, it is important to regularly consult a frequently-updated medical reference. As part of the enrollment/ procedures, the participant will be counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if the participant is considering a new over-the-counter medicine or herbal product. Please consult FDA website as appropriate: https://www.fda.gov/drugs/drug-interactions-labeling/drug-development-and-drug-interactions-table-substrates-inhibitors-and-inducers
  • Consumption of grapefruit or grapefruit products, Seville oranges, or star fruit within 3 days prior to first dose on study.
  • Participants diagnosed with another that have either received treatment within 2 years prior to first dose on study or are currently recommended to receive treatment (indicating this other malignancy is active). Exceptions include 1) participants with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone resection, 2) previous malignancy confined and surgically resected (or treated with other modalities) with curative intent are allowed, 3) any breast, reproductive or prostate cancer that is well controlled with hormonal or topical therapies.
  • Major surgery within 14 days before first dose of any study drug.
  • Participants with known, active and uncontrolled heart failure ( Class III or IV), arrhythmia, symptomatic cardiomyopathy, unstable angina or myocardial ischemia infarction within last 6 months, and clinically significant pulmonary hypertension requiring pharmacologic therapy. Clinically significant arrhythmia is defined as having one of the following: history of polymorphic ventricular fibrillation or torsade de pointes, permanent atrial fibrillation (continuous for ≥ 6 months), persistent atrial fibrillation (sustained and lasting > 7 days and/or requiring cardioversion in the 4 weeks before screening), and grade 3 atrial fibrillation (symptomatic and incompletely controlled medically in the past 6 months). Participants with paroxysmal atrial fibrillation or \< Gr 3 atrial fibrillation for period of at least 6 months are permitted to enroll provided that their rate is controlled on a stable regimen if medically indicated.
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to any assigned study agents.
  • Known allergy to both xanthine oxidase inhibitors and rasburicase.
  • Known seropositive. HIV testing is not required.
  • Participants with known, active chronic virus (HBV) infection. Exception: Participants with undetectable HBV load by polymerase chain reaction (PCR), without liver-related complications, and on definitive HBV therapy are eligible for study. Serologic evidence of prior vaccination is sufficient to participate in the trial (vaccination however is not required for trial).
  • Participants with known chronic virus (HCV) infection requiring treatment. However, if a participant with a history of HCV infection has received definitive therapy (and is now HCV viral load negative), or if a participant has a reactive HCV antibody test but has an undetectable viral load by PCR, then he/she would be eligible.
  • Immediate life-threatening, severe complications of leukemia such as uncontrolled bleeding, respiratory failure, or coagulopathy.
  • Symptomatic or (known) active CNS involvement of AML. Prophylactic intra-thecal chemotherapy is permitted.
  • Participants with active or uncontrolled infection at time of first dose of treatment on study. Prophylaxis is allowed. Participants receiving anti-microbial agents including antibiotics, antiviral or antifungal therapies are allowed if hemodynamically stable and afebrile for 72 hours (unless fever is thought to be from underlying leukemia).
  • Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that in the opinion of the investigator may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and/or would make the participant inappropriate for enrollment into this study.
  • Vaccination with live, attenuated vaccines within 4 weeks prior to initiation of study treatment or anticipation of need for such a vaccine during the study. (COVID19 vaccinations are allowed.)
  • Malabsorption syndrome or other clinically significant condition (including difficulty swallowing oral medications) that would preclude enteral administration.
  • Female participants who are lactating and breastfeeding, intention to participate in IVF (in vitro fertilization), or intending to donate eggs (ova) during course of this trial or 6 months after receiving last dose of study drug.
  • Male participants who intend to donate sperm during the course of this study or 6 months after receiving their last dose of study drug(s).
  • Participants assigned to combination venetoclax and gilteritinib are excluded with the following: Heart rate interval (QTcF) ≥ 500 msec or with other factors that increase the risk of QT prolongation or arrhythmic events (e.g., heart failure, hypokalemia, family history of long QT interval syndrome).
  • Participants assigned to combination venetoclax, azacitidine, and tagraxofusp are excluded with any clinically significant cardiac disease or abnormalities defined as:

    • is less than lower limit of normal by MUGA scan or echocardiogram.
    • Myocardial infarction, unstable angina, or evidence of poorly controlled atrial fibrillation leading to a complication or severely symptomatic such that daily activity is affected within 12 months prior to first dose on study.
    • Any history of congenital long QT syndrome sustained ventricular tachycardia requiring intervention, ventricular fibrillation, or torsades de pointes.
    • Presence at screening of second- or third-degree AV block without a permanent pacemaker, bi-fascicular block (right bundle branch block [RBBB] with left anterior hemiblock), or complete left bundle branch block.
    • QTc using Fridericia's correction (QTcF) >480 msec. Triplicate requested for tagraxofusp at screening.
  • Participants assigned to combination venetoclax, azacitidine, and revumenib are excluded with the following:

    • Participants \<40 kg in weight.
    • Concurrent use of moderate or strong inducers (prohibited)
    • LVEF is \<50% by MUGA scan or echocardiogram,
    • QTc using Fridericia's correction (QTcF) >450 msec,
    • History of acute pancreatitis within 6 months of first dose on study or history of chronic pancreatitis,
    • Known cirrhosis with a score of B or C.
    • Known personal or family history of long QT syndrome.
    • Required use of QT-prolonging agents (except for those with low risk for QT prolongation and used as standard supportive medications e.g. famotidine, Bactrim, azoles, anti-emetics, antibacterial agents such as levofloxacin, ciprofloxacin or azithromycin, diphenhydramine).
    • Any of the following within 6 months before first dose on study: myocardial infarction, uncontrolled/unstable angina, congestive heart failure (NYHA Class ≥II), life-threatening uncontrolled arrhythmia, cerebrovascular accident, or . Participants with controlled atrial fibrillation are allowed to enroll.
Terms in these criteria, in plain language(25)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Venetoclax + Low-Dose Cytarabine

    Participants receive venetoclax in combination with low-dose cytarabine (Ven/AraC). Assignment is based on evidence of drug-induced apoptotic priming from the DBP assay and confirmation that the participant meets regimen-specific eligibility requirements.

    Device: Dynamic BH3 Profiling · Drug: Venetoclax · Drug: Cytarabine

  • Experimental
    Venetoclax + Gilteritinib

    Participantsreceive venetoclax in combination with gilteritinib (Ven/Gilt). Assignment is based on evidence of drug-induced apoptotic priming from the DBP assay and confirmation that the participant meets regimen-specific eligibility requirements.

    Device: Dynamic BH3 Profiling · Drug: Venetoclax · Drug: Gilteritinib

  • Experimental
    Venetoclax + Azacitidine + Tagraxofusp

    Participants receive venetoclax, azacitidine, and tagraxofusp (Ven/Aza/Tag). Assignment is based on evidence of drug-induced apoptotic priming from the DBP assay and confirmation that the participant meets regimen-specific eligibility requirements.

    Device: Dynamic BH3 Profiling · Drug: Venetoclax · Drug: Azacitidine (AZA) · Drug: Tagraxofusp

  • Experimental
    Venetoclax + Decitabine

    Participants receive venetoclax in combination with decitabine (Ven/Dec). Assignment is based on evidence of drug-induced apoptotic priming from the DBP assay and confirmation that the participant meets regimen-specific eligibility requirements.

    Device: Dynamic BH3 Profiling · Drug: Venetoclax · Drug: Decitabine

  • Experimental
    Venetoclax + Azacitidine + Revumenib

    Participants receive venetoclax, azacitidine, and revumenib (Ven/Aza/Rev). Assignment is based on evidence of drug-induced apoptotic priming from the DBP assay and confirmation that the participant meets regimen-specific eligibility requirements.

    Device: Dynamic BH3 Profiling · Drug: Venetoclax · Drug: Azacitidine (AZA) · Drug: Revumenib

  • Experimental
    Venetoclax + Cladribine-Based Regimen

    Participants receive a 28-day-cycle venetoclax and cladribine-based regimen. The low-intensity strategy is intended for participants older than 70 years or medically unfit and consists of venetoclax, cladribine, and low-dose cytarabine. The mid-intensity strategy is intended for fit participants 70 years or younger and consists of venetoclax, cladribine, and mid-dose cytarabine. For the low-intensity strategy, venetoclax is administered on Days 1-21. Cladribine 5 mg/m² is administered daily on Days 1-5, and cytarabine 20 mg is administered twice daily on Days 1-10. Induction may continue for up to two cycles according to response. Venetoclax dose and duration may be modified for tolerability and drug interactions. For the mid-intensity strategy, venetoclax is administered on Days 2-8. Cladribine 5 mg/m² is administered daily on Days 1-5, and cytarabine is administered once daily on Days 1-5 (age-adjusted). Induction may continue for up to two cycles according to response.

    Device: Dynamic BH3 Profiling · Drug: Venetoclax · Drug: Cladribine (CLAD)

Interventions

  • DeviceDynamic BH3 Profiling

    Dynamic BH3 Profiling is performed on myeloblasts obtained from a bone marrow aspirate to assess drug-induced apoptotic priming, using cytochrome c retention as the assay readout. The report evaluates venetoclax-based combinations and includes comparisons that are intra-patient and inter-patient (against a pooled historical dataset). The Protocol Tumor Board reviews the DBP report, screening findings, drug-specific eligibility, and patient and disease history to determine treatment assignment. The protocol defines feasibility as successful assay performance and delivery of the DBP report within five days of sample receipt.

  • DrugVenetoclax

    Venetoclax is a selective BCL-2 inhibitor administered as a component of every protocol treatment regimen. Target dose and duration are specific to each treatment regimen. Doses may be reduced when given with azoles or other interacting agents, and treatment may be held for clinically significant tumor lysis syndrome.

  • DrugCytarabine

    Cytarabine will be tested in combination with venetoclax at different dosing strategies. Low-dose cytarabine will be combined with venetoclax in Arm 1. It is also administered as part of the venetoclax-cladribine-based regimen in Arm 6, at low or mid-intensity dosing based on age and fitness, and will be age-adjusted for safety.

  • DrugGilteritinib

    Gilteritinib is administered in combination with venetoclax to participants assigned to Treatment 2 based on DBP findings and confirmation of regimen-specific eligibility.

  • DrugAzacitidine (AZA)

    Azacitidine is administered with venetoclax and tagraxofusp in Arm 3 and with venetoclax and revumenib in Arm 5. Dosing of azacitidine is standard at 75 mg/m² daily on Days 1-7.

  • DrugTagraxofusp

    Tagraxofusp is administered in combination with venetoclax and azacitidine to participants assigned to Treatment 3 based on DBP findings and confirmation of regimen-specific eligibility.

  • DrugDecitabine

    Decitabine is administered in combination with venetoclax to participants assigned to Treatment 4 based on DBP findings and confirmation of regimen-specific eligibility.

  • DrugRevumenib

    Revumenib is administered orally and in combination with venetoclax and azacitidine to participants assigned to Treatment 3 based on DBP findings and confirmation of regimen-specific eligibility.

  • DrugCladribine (CLAD)

    Cladribine is administered with venetoclax and low- or mid-intensity cytarabine in a combination regimen. ladribine is administered at 5 mg/m² daily on Days 1-5 of a 28-day cycle.

07

What researchers measure

Primary outcomes

  1. Feasibility Rate of Dynamic BH3 Profiling (DBP)

    Feasibility rate is defined as the proportion of participants whose bone marrow specimens are collected and received by the laboratory for DBP testing, for whom the samples are successfully processed and a DBP report is generated.

    Time frame: Within 5 days of receipt of a viable sample.

  2. Overall Response Rate (ORR)

    ORR is defined as the proportion of participants with relapsed/refractory acute myeloid leukemia (R/R AML) assigned to protocol therapy by the Protocol Tumor Board who achieve complete remission (CR), complete remission with partial hematologic recovery (CRh), or complete remission with incomplete count recovery (CRi), according to the European LeukemiaNet (ELN) response criteria for AML. CR requires bone marrow blasts \<5%, absence of circulating blasts and extramedullary disease, absolute neutrophil count (ANC) ≥1,000/μL, and platelet count ≥100,000/μL. CRh requires all other CR criteria to be met, with ANC ≥500/μL and platelet count ≥50,000/μL. CRi requires all other CR criteria to be met, but with ANC \<1,000/μL and/or platelet count \<100,000/μL.

    Time frame: Assessed at the end of Cycles 1, 2, and 4 (each cycle is 28 days), and every 3 cycles thereafter for up to 1 year, with an end-of-treatment assessment (up to 2 years; up to 3 months or 2 cycles for the cladribine/venetoclax arm).

  3. Reasons for Unsuccessful Assignment to DBP-Guided Therapy

    Reasons for unsuccessful assignment to protocol therapy despite available drug nominations from DBP, or participant withdrawal, will be summarized by category using frequencies and percentages.

    Time frame: During the screening period (up to 21 days).

Secondary outcomes

  1. Grade 3 or Higher Hematologic Adverse Events Rate

    Grade 3 or higher hematologic adverse events rate is defined as the proportion of participants who experience at least one Grade 3 or higher hematologic adverse event, as graded according to the Common Terminology Criteria for Adverse Events (CTCAE) version 6.0.

    Time frame: Assessed at each scheduled treatment visit (each cycle is 28 days) and 30 days after the last dose of study treatment (up to 2 years plus 30 days; up to 3 months or 2 cycles plus 30 days for the cladribine/venetoclax arm).

  2. Grade 3 or Higher Non-Hematologic Adverse Events Rate

    Grade 3 or higher non-hematologic adverse events rate is defined as the proportion of participants who experience at least one Grade 3 or higher non-hematologic adverse event, as graded according to the Common Terminology Criteria for Adverse Events (CTCAE) version 6.0.

    Time frame: Assessed at each scheduled treatment visit (each cycle is 28 days) and 30 days after the last dose of study treatment (anticipated up to 2 years plus 30 days; up to 3 months or 2 cycles plus 30 days for the cladribine/venetoclax arm).

  3. Overall Response Rate (ORR) by Assigned Treatment Regimen

    Grade 3 or higher non-hematologic adverse events rate is defined as the proportion of participants who experience at least one Grade 3 or higher non-hematologic adverse event, as graded according to the Common Terminology Criteria for Adverse Events (CTCAE) version 6.0.

    Time frame: Assessed at each scheduled treatment visit (each cycle is 28 days) and 30 days after the last dose of study treatment (up to 2 years plus 30 days; up to 3 months or 2 cycles plus 30 days for the cladribine/venetoclax arm).

  4. Overall Response Rate (ORR) by Each Treatment Regimen

    ORR is defined as the proportion of participants with relapsed/refractory acute myeloid leukemia (R/R AML) assigned to protocol therapy by the Protocol Tumor Board who achieve complete remission (CR), complete remission with partial hematologic recovery (CRh), or complete remission with incomplete count recovery (CRi), according to the ELN response criteria for AML. CR requires bone marrow blasts \<5%, absence of circulating blasts and extramedullary disease, absolute neutrophil count (ANC) ≥1,000/μL, and platelet count ≥100,000/μL. CRh requires all other CR criteria to be met, with ANC ≥500/μL and platelet count ≥50,000/μL. CRi requires all other CR criteria to be met, but with ANC \<1,000/μL and/or platelet count \<100,000/μL.

    Time frame: Assessed at the end of Cycles 1, 2, and 4 (each cycle is 28 days), and every 3 cycles thereafter for up to 1 year, with an end-of-treatment assessment (up to 2 years; up to 3 months or 2 cycles for the cladribine/venetoclax arm).

  5. Duration of Response (DOR)

    DOR is measured from the time response criteria are first met for CR, CRi, CRh, or complete remission with incomplete platelet recovery (CRp), whichever occurs first, until the first date of objectively documented recurrent or progressive disease. According to the ELN response criteria for AML, CR requires bone marrow blasts \<5%, absence of circulating blasts and extramedullary disease, ANC ≥1,000/μL, and platelet count ≥100,000/μL. CRi meets all other CR criteria but has ANC \<1,000/μL and/or platelet count \<100,000/μL. CRh meets all other CR criteria with ANC ≥500/μL and platelet count ≥50,000/μL. CRp meets all other CR criteria but has platelet count \<100,000/μL with ANC ≥1,000/μL. Recurrent disease is defined as the reappearance of disease following CR, CRh, or CRi, characterized by bone marrow blasts ≥5%, reappearance of blasts in at least two peripheral blood samples collected at least one week apart, or development of extramedullary disease. Disease progression is defined accord

    Time frame: Assessed at each scheduled treatment visit (each cycle is 28 days) and 30 days after the last dose of study treatment (up to 2 years plus 30 days; up to 3 months or 2 cycles plus 30 days for the cladribine/venetoclax arm).

  6. 6-Month Progression-Free Survival (PFS6)

    PFS6 is the percent probability estimate at 6 months based on the Kaplan-Meier method. PFS is measured from the start of study treatment to the first documented disease progression or death from any cause, whichever occurs first. Participants alive without disease progression are censored at the date of last follow-up. Disease progression is defined according to the ELN 2017 criteria as a \>50% increase in bone marrow blasts from baseline (with a minimum 15-percentage-point increase for patients with \<30% blasts at baseline), persistent bone marrow blasts \>70% for at least 3 months without the specified hematologic improvement, a \>50% increase in peripheral blood blasts to \>25 × 10⁹/L in the absence of differentiation syndrome, or the development of new extramedullary disease.

    Time frame: From the start of study treatment to 6 months, with disease assessments at the end of Cycles 1, 2, and 4, and every 3 cycles thereafter (each cycle is 28 days).

  7. 12-month Progression-Free Survival (PFS12)

    PFS12 is the percent probability estimate at 12 months based on the Kaplan-Meier method. PFS is measured from the start of study treatment to the first documented disease progression or death from any cause, whichever occurs first. Participants alive without disease progression are censored at the date of last follow-up. Disease progression is defined according to the ELN 2017 criteria as a \>50% increase in bone marrow blasts from baseline (with a minimum 15-percentage-point increase for patients with \<30% blasts at baseline), persistent bone marrow blasts \>70% for at least 3 months without the specified hematologic improvement, a \>50% increase in peripheral blood blasts to \>25 × 10⁹/L in the absence of differentiation syndrome, or the development of new extramedullary disease.

    Time frame: From the start of study treatment to 12 months, with disease assessments at the end of Cycles 1, 2, and 4, and every 3 cycles thereafter (each cycle is 28 days).

  8. 6-month Overall Survival (OS6)

    OS6 is the percent probability estimate at 6 months based on the Kaplan-Meier method. OS is defined as the time from start of study treatment to death due to any cause or censored at date last known alive. All surviving participants will be censored at time of final follow up.

    Time frame: At 6 months after the start of study treatment

  9. 12-month Overall Survival (OS12)

    OS12 is the percent probability estimate at 12 months based on the Kaplan-Meier method. OS is defined as the time from start of study treatment to death due to any cause or censored at date last known alive. All surviving participants will be censored at time of final follow up.

    Time frame: At 12 months after the start of study treatment

08

Study locations

2 sites
09

References and documents

Individual participant data

Plan to share: Yes — The Harvard Cancer Consortium encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to: Jacqueline Garcia. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.

Supporting information: Study protocol, Statistical analysis plan

Time frame: Data can be shared no earlier than 1 year following the date of publication

Access criteria: Contact the Belfer office for Dana -Farber Innovations (BODFI) at innovations@dfci.harvard.edu

No publications or documents are linked to this record.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Mar 2027; primary completion for Dec 2029, 33 months later.

Of 385 non-industry phase 2 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 66 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 107. This study's planned 33 months is below that.

Counting every sponsor, half of 442 studies reached it within 60 months; a quarter within 38 and three quarters within 104.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 14, 2026
First posted
Nov 19, 2026
StartEst.
Mar 6, 2027
Primary completionEst.
Dec 31, 2029
CompletionEst.
Jul 31, 2030
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT07949370
Responsible party
Jacqueline Garcia, MD (Principal Investigator, Dana-Farber Cancer Institute) — Principal investigator
First posted
Nov 19, 2026
Start date
Mar 6, 2027 (estimated)
Primary completion
Dec 31, 2029 (estimated)
Completion
Jul 31, 2030 (estimated)
Last update
Nov 19, 2026

Study contacts

Jacqueline Garcia, MD
Contact
Jacqueline_Garcia@dfci.harvard.edu
617-632-1906
Jacqueline S Garcia, MD
principal investigator · Dana-Farber Cancer Institute

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion